SOURCE: BioTech Medics, Inc.

January 11, 2007 09:59 ET

BioTech Medics, Inc. Announces Hiring of James Nairne as Chief Financial Officer

CARSON CITY, NV -- (MARKET WIRE) -- January 11, 2007 -- The Board of Directors of BioTech Medics, Inc. (PINKSHEETS: BTMD) has announced the hiring of James Nairne, Chartered Accountant, as Chief Financial Officer.

Mr. Nairne has prior medical laser experience as Managing Partner of Medical Laser Therapeutics, L.P. He also has extensive prior venture capital experience as the Managing Director of Venture Capital for BP Capital, LP, the investment arm of T. Boone Pickens and an Investment Partner with Best, Patterson & Crothers, Ltd.

Mr. Nairne has over 32 years experience as an accountant. He is a member of the Canadian Institute of Chartered Accountants and the Institute of Chartered Accountants of Manitoba, Canada.

The goal of the Company has been to become a reporting company and to become eligible on the OTCBB. The hiring of Mr. Nairne should help expedite this goal.

BioTech Medics operates a Pain Management & Wellness Center in Dallas, Texas, and offers alternative means of treatment with the NeuroLase Therapeutic Medical Laser. The NeuroLase has FDA clearance for the temporary relief of muscular, skeletal and arthritic pain.

BioTech Medics also distributes exclusively the patented SHBAN Solution, which is a unique non-toxic odorless product which kills various bacteria, viruses, mold and fungus. SHBAN was recently tested and proven to kill the Avian Bird Flu Virus.

Safe Harbor for Forward-Looking Statements.

This press contains statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to complete the planned accounting and financial statements

Contact Information

  • Contact:
    Investor Relations
    Phone: 1-800-200-2458